{"id":"https://openalex.org/W2038091919","doi":"https://doi.org/10.1097/00003246-200101000-00003","title":"The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis","display_name":"The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis","publication_year":2001,"publication_date":"2001-01-01","ids":{"openalex":"https://openalex.org/W2038091919","doi":"https://doi.org/10.1097/00003246-200101000-00003","mag":"2038091919","pmid":"https://pubmed.ncbi.nlm.nih.gov/11176151"},"language":"en","primary_location":{"id":"doi:10.1097/00003246-200101000-00003","doi":"https://doi.org/10.1097/00003246-200101000-00003","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00003246-200101000-00003","pdf_url":null,"source":{"id":"https://openalex.org/S108732581","display_name":"Critical Care Medicine","issn_l":"0090-3493","issn":["0090-3493","1530-0293"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical Care Medicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025379878","display_name":"Steven M. Opal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2801290373","display_name":"Memorial Hospital of Rhode Island","ror":"https://ror.org/04c0a2j77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801290373"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Opal","raw_affiliation_strings":["Brown University School of Medicine, Providence, RI, USA. steven_opal@brown.edu","Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","Supported, in part, by a grant from Chiron Corp., Emeryville, CA","The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University School of Medicine, Providence, RI, USA. steven_opal@brown.edu","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I2801290373"]},{"raw_affiliation_string":"From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","institution_ids":[]},{"raw_affiliation_string":"Supported, in part, by a grant from Chiron Corp., Emeryville, CA","institution_ids":[]},{"raw_affiliation_string":"The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110192921","display_name":"John E. Palardy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2801290373","display_name":"Memorial Hospital of Rhode Island","ror":"https://ror.org/04c0a2j77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801290373"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John E. Palardy, BA","raw_affiliation_strings":["Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","Supported, in part, by a grant from Chiron Corp., Emeryville, CA","The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I2801290373"]},{"raw_affiliation_string":"From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","institution_ids":[]},{"raw_affiliation_string":"Supported, in part, by a grant from Chiron Corp., Emeryville, CA","institution_ids":[]},{"raw_affiliation_string":"The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041825917","display_name":"Nicolas A. Parejo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2801290373","display_name":"Memorial Hospital of Rhode Island","ror":"https://ror.org/04c0a2j77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801290373"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicolas A. Parejo, BA","raw_affiliation_strings":["Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","Supported, in part, by a grant from Chiron Corp., Emeryville, CA","The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I2801290373"]},{"raw_affiliation_string":"From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","institution_ids":[]},{"raw_affiliation_string":"Supported, in part, by a grant from Chiron Corp., Emeryville, CA","institution_ids":[]},{"raw_affiliation_string":"The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070471873","display_name":"Abla A. Creasey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2801290373","display_name":"Memorial Hospital of Rhode Island","ror":"https://ror.org/04c0a2j77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801290373"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abla A. Creasey","raw_affiliation_strings":["Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals","Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","Supported, in part, by a grant from Chiron Corp., Emeryville, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"The results of these experiments indicate that recombinant human tissue factor pathway inhibitor has a significant survival advantage after superantigen-induced shock and polymicrobial intra-abdominal sepsis in experimental animals","institution_ids":[]},{"raw_affiliation_string":"Address requests for reprints to: Steven M. Opal, MD, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I2801290373"]},{"raw_affiliation_string":"From Brown University School of Medicine (Dr. Opal and Mr. Palardy and Parejo), Providence, RI, and Chiron Corp. (Dr. Creasey), Emeryville, CA","institution_ids":["https://openalex.org/I27804330"]},{"raw_affiliation_string":"Presented, in part, at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26, 1999 (abstract 261)","institution_ids":[]},{"raw_affiliation_string":"Supported, in part, by a grant from Chiron Corp., Emeryville, CA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.0899,"has_fulltext":false,"cited_by_count":68,"citation_normalized_percentile":{"value":0.97404387,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"29","issue":"1","first_page":"13","last_page":"17"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10218","display_name":"Sepsis Diagnosis and Treatment","score":0.9570000171661377,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10218","display_name":"Sepsis Diagnosis and Treatment","score":0.9570000171661377,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11116","display_name":"Trauma, Hemostasis, Coagulopathy, Resuscitation","score":0.01810000091791153,"subfield":{"id":"https://openalex.org/subfields/2706","display_name":"Critical Care and Intensive Care Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tissue-factor-pathway-inhibitor","display_name":"tissue factor pathway inhibitor","score":0.9739999771118164},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.6980000138282776},{"id":"https://openalex.org/keywords/polymicrobial-sepsis","display_name":"polymicrobial sepsis","score":0.8019999861717224},{"id":"https://openalex.org/keywords/cecal-ligation-and-puncture","display_name":"cecal ligation and puncture","score":0.9319999814033508},{"id":"https://openalex.org/keywords/peritonitis","display_name":"peritonitis","score":0.9520000219345093},{"id":"https://openalex.org/keywords/staphylococcal-enterotoxin-b","display_name":"staphylococcal enterotoxin B","score":0.9570000171661377},{"id":"https://openalex.org/keywords/lipopolysaccharide","display_name":"lipopolysaccharide","score":0.9890000224113464},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.8840000033378601},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.45500001311302185},{"id":"https://openalex.org/keywords/recombinant-protein-therapy","display_name":"recombinant protein therapy","score":0.628000020980835},{"id":"https://openalex.org/keywords/hemostasis","display_name":"hemostasis","score":0.43799999356269836},{"id":"https://openalex.org/keywords/blood-coagulation","display_name":"coagulation","score":0.4410000145435333},{"id":"https://openalex.org/keywords/inflammatory-markers","display_name":"inflammatory markers","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C36333154","wikidata":"https://www.wikidata.org/wiki/Q772950","display_name":"Superantigen","level":4,"score":0.9147613048553467},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8536322712898254},{"id":"https://openalex.org/C2777397205","wikidata":"https://www.wikidata.org/wiki/Q275792","display_name":"Saline","level":2,"score":0.6767805218696594},{"id":"https://openalex.org/C2778384902","wikidata":"https://www.wikidata.org/wiki/Q183134","display_name":"Sepsis","level":2,"score":0.5991523861885071},{"id":"https://openalex.org/C2778754761","wikidata":"https://www.wikidata.org/wiki/Q421804","display_name":"Lipopolysaccharide","level":2,"score":0.5378443598747253},{"id":"https://openalex.org/C2781300812","wikidata":"https://www.wikidata.org/wiki/Q178061","display_name":"Shock (circulatory)","level":2,"score":0.48963814973831177},{"id":"https://openalex.org/C2777628635","wikidata":"https://www.wikidata.org/wiki/Q1765564","display_name":"Septic shock","level":3,"score":0.4887208938598633},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.4729195237159729},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4240986704826355},{"id":"https://openalex.org/C66999527","wikidata":"https://www.wikidata.org/wiki/Q421978","display_name":"Enterotoxin","level":4,"score":0.41501113772392273},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3788587152957916},{"id":"https://openalex.org/C16685009","wikidata":"https://www.wikidata.org/wiki/Q335057","display_name":"Andrology","level":1,"score":0.3488357663154602},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33080047369003296},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.11495062708854675},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08620420098304749},{"id":"https://openalex.org/C547475151","wikidata":"https://www.wikidata.org/wiki/Q25419","display_name":"Escherichia coli","level":3,"score":0.08530983328819275},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.07369732856750488},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004731","descriptor_name":"Endotoxins","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008074","descriptor_name":"Lipoproteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010538","descriptor_name":"Peritonitis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010538","descriptor_name":"Peritonitis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D010538","descriptor_name":"Peritonitis","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D011897","descriptor_name":"Random Allocation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012772","descriptor_name":"Shock, Septic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012772","descriptor_name":"Shock, Septic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D012772","descriptor_name":"Shock, Septic","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D013210","descriptor_name":"Staphylococcus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018089","descriptor_name":"Superantigens","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018709","descriptor_name":"Statistics, Nonparametric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00003246-200101000-00003","doi":"https://doi.org/10.1097/00003246-200101000-00003","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00003246-200101000-00003","pdf_url":null,"source":{"id":"https://openalex.org/S108732581","display_name":"Critical Care Medicine","issn_l":"0090-3493","issn":["0090-3493","1530-0293"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical Care Medicine","raw_type":"journal-article"},{"id":"pmid:11176151","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11176151","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical care medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W78888789","https://openalex.org/W1911737152","https://openalex.org/W1932895848","https://openalex.org/W1985988133","https://openalex.org/W2003915950","https://openalex.org/W2005668158","https://openalex.org/W2019050518","https://openalex.org/W2023380183","https://openalex.org/W2043806332","https://openalex.org/W2079183569","https://openalex.org/W2092993771","https://openalex.org/W2118902632","https://openalex.org/W2157766752","https://openalex.org/W2160388336","https://openalex.org/W2217969591","https://openalex.org/W2250168035","https://openalex.org/W2254837471","https://openalex.org/W2273695375","https://openalex.org/W2403028551","https://openalex.org/W2413121069","https://openalex.org/W2413763513"],"related_works":["https://openalex.org/W1994144487","https://openalex.org/W2025015505","https://openalex.org/W2083395689","https://openalex.org/W2043806332","https://openalex.org/W2118902632","https://openalex.org/W88725756","https://openalex.org/W2350196366","https://openalex.org/W7096938301","https://openalex.org/W2077834849","https://openalex.org/W2410098916"],"abstract_inverted_index":{"OBJECTIVES:":[0],"To":[1],"study":[2],"recombinant":[3],"human":[4],"tissue":[5],"factor":[6,325],"pathway":[7,326],"inhibitor":[8,327],"(rhTFPI)":[9],"in":[10,16,26,167,179,237,319,333,346],"a":[11,17,91,134,199],"superantigen-induced":[12,58,336],"shock":[13,59,337],"model":[14,23],"and":[15,20,47,90,111,170,188,294,311,338],"cecal":[18],"ligation":[19],"puncture":[21],"(CLP)":[22],"of":[24,94,191,202,205,335],"peritonitis":[25],"mice.":[27],"DESIGN:":[28],"Prospective,":[29],"randomized,":[30],"experimental":[31,35],"study.":[32],"SETTING:":[33],"An":[34],"animal":[36],"research":[37],"laboratory.":[38],"SUBJECTS:":[39],"Eighty":[40],"BALB/c":[41,49],"mice":[42,50],"for":[43,51,79,129,146,349],"the":[44,52,57,118,168,180,194,231,245,257,261,278,320,330],"superantigen":[45],"model,":[46,60,120],"56":[48],"CLP":[53,119,246,276],"model.":[54],"INTERVENTIONS:":[55],"In":[56,117,244],"animals":[61,197,249],"received":[62,105,185],"rhTFPI":[63,121,267,302],"(350":[64],"mg/kg)":[65],"subcutaneously":[66],"every":[67,126],"12":[68],"hrs":[69,81,128,131],"(n":[70,76,108,114,137,143,153],"=":[71,77,109,115,138,144,154,309,314],"30)":[72,78],"or":[73,122,140,241],"saline":[74,123,181],"control":[75,151,172,182,232,258],"60":[80],"after":[82,260,275],"staphylococcal":[83],"enterotoxin":[84],"B":[85],"(SEB;":[86],"10":[87],"microg":[88,101],"iv)":[89],"sublethal":[92],"dose":[93],"E.":[95],"coli":[96],"0111:B4":[97],"lipopolysaccharide":[98],"(LPS;":[99],"75":[100],"ip).":[102],"Control":[103],"groups":[104],"SEB":[106,169,187],"alone":[107,113],"10)":[110,155],"LPS":[112,171,189,307],"10).":[116],"was":[124,156,164,177],"given":[125],"8":[127],"48":[130],"by":[132,301],"using":[133],"21-gauge":[135],"needle":[136,142,264,280],"9)":[139],"23-gauge":[141],"14)":[145],"CLP.":[147],"A":[148],"sham":[149],"surgery":[150],"group":[152,183,212,233,259,268],"also":[157],"included.":[158],"MEASUREMENTS":[159],"AND":[160],"MAIN":[161],"RESULTS:":[162],"There":[163],"0%":[165],"mortality":[166,175,200,273,331],"groups.":[173],"The":[174,210,266],"rate":[176,201,274,332],"64%":[178],"that":[184],"both":[186],"(19":[190],"30),":[192],"whereas":[193],"rhTFPI-":[195],"treated":[196],"had":[198,213,269],"20%":[203],"(6":[204],"30;":[206],"p":[207,227,287],"<":[208,228,288],".01).":[209,289],"rhTFPI-treated":[211,248],"significantly":[214,270,305,328],"lower":[215],"interleukin-6":[216],"levels":[217,298,316],"(61.8":[218],"+/-":[219,224],"41":[220],"pg/mL":[221],"vs.":[222,284],"285":[223],"63":[225],"pg/mL;":[226],".05)":[229],"than":[230],"but":[234,304],"no":[235],"differences":[236],"tumor":[238,295],"necrosis":[239,296],"factor-alpha":[240,297],"interferon-gamma":[242],"levels.":[243],"experiment,":[247],"did":[250],"not":[251],"have":[252],"any":[253],"survival":[254],"advantage":[255],"over":[256],"large-bore":[262],"(21-gauge)":[263],"puncture.":[265],"improved":[271],"7-day":[272],"with":[277],"small-bore":[279],"(23-gauge;":[281],"21.4%":[282],"[rhTFPI]":[283],"71.4%":[285],"[control],":[286],"Plasma":[290],"LPS,":[291],"interleukin-6,":[292],"interferon-gamma,":[293],"were":[299,317],"unchanged":[300],"treatment,":[303],"reduced":[306],"(p":[308,313],".006)":[310],"IFNgamma":[312],".001)":[315],"found":[318],"peritoneal":[321],"fluid.":[322],"CONCLUSIONS:":[323],"Tissue":[324],"improves":[329],"models":[334],"polymicrobial":[339],"intra-abdominal":[340],"infection,":[341],"supporting":[342],"its":[343],"potential":[344],"use":[345],"clinical":[347],"trials":[348],"septic":[350],"shock.":[351]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}